Search
Lexaria Bioscience Corp
LEXXAdd to Watchlist
0.560USD
-0.012-2.08%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
13.94MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.08%
5 Days
+5.68%
1 Month
-11.93%
6 Months
-14.36%
Year to Date
-9.22%
1 Year
-37.77%
Key Figures
0.570Open
0.600High
49.03KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.20%Turnover Ratio
0.572Prev. Close
0.560Low
24.97KTurnover
LossP/E Static
2.11P/B
0.00%Div Yield TTM
-125.79%ROA
1.55052wk High
2.10Volume Ratio
-11.90MNet Profit
24.89MShares
-0.4768EPS TTM
0.35Beta
-138.64%ROE
0.46052wk Low
7.01%Amplitude
100.00%Gross Margin
13.94MMarket Cap
-1.65Reward/Risk
6.10%Risk Rate
TradingKey Stock Score of Lexaria Bioscience Corp
Currency: USD Updated: 2026-07-02Key Insights
Lexaria Bioscience Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 111 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.75.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lexaria Bioscience Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lexaria Bioscience Corp Highlights
StrengthsRisks
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 212.07% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 705.92K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 705.92K.
Overvalued
The company’s latest PE is -1.17, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.64M shares, decreasing 59.12% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 20.76K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.74.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
3.750
Target Price
+555.59%
Upside Space
Lexaria Bioscience Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lexaria Bioscience Corp Info
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Ticker SymbolLEXX
CompanyLexaria Bioscience Corp
CEOChristopher (Richard)
Websitehttps://www.lexariabioscience.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Lexaria Bioscience Corp (LEXX)?
The current price of Lexaria Bioscience Corp (LEXX) is 0.56.
What is the symbol of Lexaria Bioscience Corp?
The ticker symbol of Lexaria Bioscience Corp is LEXX.
What is the 52-week high of Lexaria Bioscience Corp?
The 52-week high of Lexaria Bioscience Corp is 1.55.
What is the 52-week low of Lexaria Bioscience Corp?
The 52-week low of Lexaria Bioscience Corp is 0.46.
What is the market capitalization of Lexaria Bioscience Corp?
The market capitalization of Lexaria Bioscience Corp is 13.94M.
Is Lexaria Bioscience Corp (LEXX) currently rated as Buy, Hold, or Sell?
According to analysts, Lexaria Bioscience Corp (LEXX) has an overall rating of Buy, with a price target of 3.75.
What is the Earnings Per Share (EPS TTM) of Lexaria Bioscience Corp (LEXX)?
The Earnings Per Share (EPS TTM) of Lexaria Bioscience Corp (LEXX) is -0.66.